NASDAQ:SMLR Semler Scientific Q2 2024 Earnings Report $32.54 -4.16 (-11.34%) As of 05/14/2025 04:00 PM Eastern Earnings HistoryForecast Semler Scientific EPS ResultsActual EPS$0.64Consensus EPS $0.56Beat/MissBeat by +$0.08One Year Ago EPSN/ASemler Scientific Revenue ResultsActual Revenue$14.47 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASemler Scientific Announcement DetailsQuarterQ2 2024Date8/5/2024TimeAfter Market ClosesConference Call DateMonday, August 5, 2024Conference Call Time4:30PM ETConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Semler Scientific Q2 2024 Earnings Call TranscriptProvided by QuartrAugust 5, 2024 ShareLink copied to clipboard.There are 5 speakers on the call. Operator00:00:01Good afternoon and welcome to the Semler Scientific 20 24 Second Quarter Financial Results Conference Call. Submitted prior to this call via e mail. Please note, this event is being recorded. Before we begin, Semler Scientific needs to remind you that certain comments made during this call may constitute forward looking statements and are made pursuant to and within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 as amended. These include statements regarding the expectations for expansion of the business and the development and the marketing of additional products, including receipt and timing of an additional 510 clearance for QuantaFlo and our recently adopted Bitcoin treasury strategy and plans to acquire additional Bitcoin. Operator00:01:10Such forward looking statements are subject to both known and unknown risks and uncertainties that could cause actual results to differ materially from such statements. Those risks and uncertainties are described in the press release and our SEC filings. The forward looking statements made today are as of the date of this call and the company does not undertake any obligation to update the forward looking statements. If you do not have a copy of today's release, you may obtain 1 by visiting the Investor Relations page of the website, semlarscientific.com. Now, I would like to introduce Doug Murphy Katorian, CEO of Semler Scientific. Operator00:01:51Please go ahead. Speaker 100:01:53Good afternoon, everybody. Thank you for joining our Q2 2024 results call. Once again, we achieved a strong interim from operations and used most of our cash and cash equivalents to purchase a bitcoin. We now hold a 929 bitcoins as of August 5, 2024. Now I'd like to hand the call over to Erik Semler, our Chairman, who will discuss our Bitcoin strategy in more detail. Speaker 200:02:34Eric? Thank you, Doug. It's great to be on the call today. In May, we announced that our Board of Directors adopted Bitcoin as our primary treasury reserve asset. We are very encouraged by the strong positive reaction to this announcement. Speaker 200:02:52We are in the fortunate position of being a company with a strong balance sheet, driven by a high margin business that has consistently generated cash. We are also fortunate that our Board members and executive officers collectively beneficially own approximately 30% of the company's outstanding shares and are intensely focused on maximizing shareholder value. Our Board and senior management have spent extensive time examining potential uses of cash, including acquisitions and stock repurchases. But after studying various alternatives, we decided that holding Bitcoin would be the best use of our cash. We view Bitcoin as a compelling investment. Speaker 200:03:39We are encouraged by the growing global acceptance and institutionalization of Bitcoin, which has been accelerated by the SEC's approval in January 2024 of 11 Bitcoin Spot ETFs. These ETFs have reported tens of 1,000,000,000 of dollars of net inflows with investments from a large number of institutions, including global banks, pensions, endowments and registered investment advisers. It is currently estimated that more than 10% of all bitcoins are now held by institutions. We believe Bitcoin has unique attributes as a scarce and finite asset that can serve as a reasonable inflation hedge and safe haven amid global instability. Bitcoin is often compared to gold, which has been viewed as a dependable store of value throughout history. Speaker 200:04:30Like gold, Bitcoin is viewed as a scarce asset. The ultimate supply of Bitcoin is limited to 21,000,000 coins and approximately 94% of its supply already exists. We believe that Bitcoin's finite, digital and decentralized nature, as well as its architectural resilience make it preferable to gold, which has a market capitalization more than 16 times higher than the market cap of Bitcoin. Given our view that Bitcoin is a comparable and possibly better store of value than gold, we believe that Bitcoin will approach or exceed the value of gold over time. In light of the substantial gap in value between gold and Bitcoin, we believe that Bitcoin has the potential to generate outsized returns as it gains increasing acceptance as digital gold. Speaker 200:05:26We are highly committed to our Bitcoin strategy. As an operating company, we intend to use our cash flow as well as proceeds from equity capital raises to accumulate Bitcoin. Now, I'm pleased to introduce our COO, Jennifer Oliva Harrington to provide an overview and update of our core medical products and services business. Jen? Speaker 300:05:49Thank you, Eric. Today, I will be presenting an overview of our market developments and opportunities. Renee Cormier, our CFO, will be providing information about Q2 2024 financial results. Semler is a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases. In conjunction with our Bitcoin treasury strategy, we will continue to focus on our core medical products and services business. Speaker 300:06:19We remain dedicated to our customers and our goal of operating a growing and profitable healthcare company. Our main product, QuantaFlo, is a medical device that is a non invasive point of care test that measures arterial blood flow in the extremities to aid clinicians in the early diagnosis of peripheral arterial disease or PAD. Our technology brings cardiovascular testing to the front lines of medicine. We have a high leverage distribution model as quantiflo was sold on a SaaS basis with a high recurring revenue stream from this subscription based licensing model that has a large and underpenetrated TAM. Sendler's operating focus remains supporting the identification of chronic diseases by our customers, which continues to burden our healthcare system. Speaker 300:07:10Cardiovascular disease ranks as a top concern in healthcare expenditures and global mortality, underscoring the imperative for early identification of cardiac existing products and data services to stay in the forefront of innovation and consistently deliver cutting edge solutions to our customers. Our long term vision includes extending our reach to encompass additional cardiovascular applications, reflecting dedication to continuous expansion. In the interim, we continue the promotion and selling of QuantaFlo as a valuable aid in the diagnosis of PAD. We continue seeking to further establish QuantaFlo as standard of care for our PAD diagnosis, leveraging the demonstrated clinical benefit of early detection and preventative care. We believe this approach holds the potential to not only save lives, but also to lower healthcare expenditures. Speaker 300:08:13We will continue diversifying our customer base by adding new medical centers, expanding our reach within value based care providers and growing opportunities within additional markets that will benefit from PAD testing. I will now turn the call over to Renee to discuss our financial highlights. Speaker 400:08:32Thank you, Jen. I'll cover our Q2 financial results and then speak more about our Bitcoin holdings and recently filed S 3. Following our remarks and as time permits, we will answer questions that have been submitted via email. Total revenues in Q2 2024 were $14,500,000 which was down about 22% compared to the Q2 of 2023. For the remainder of 2024, we anticipate our revenues could follow a similar cadence that we saw in 2023, with H1 more heavily weighted versus H2. Speaker 400:09:11In the Q2 of 2024, our 3 largest customers, including their related affiliates, comprised 44%, 27% and 11% of quarterly revenues, respectively. Operating expenses in Q2 2024, which includes cost of revenues, were $9,100,000 a decrease of 20% year over year. Income from operations was $5,400,000 compared to $7,200,000 in the prior year. For the remainder of the year, we are focused on tight expense control as we continue to implement our Bitcoin treasury strategy. Other expenses net was $4,200,000 and included the change in fair value of our Bitcoin holdings of negative $5,100,000 We have elected to early adopt ASU 20,203, which is the new standard issued by the FASB for accounting for and disclosure of crypto assets. Speaker 400:10:20ASU 20,203,008 requires Bitcoin assets to be measured at fair value with gains and losses from changes in the fair value to be recognized in net income for each reporting period. While this may introduce volatility into our reported net income, it will not impact our cash flow from operations, which we intend to invest in additional Bitcoin purchases. Net income was nil or $0 per basic share and $0 per fully diluted share compared to net income of $5,900,000 or $0.88 per basic share and $0.75 per fully diluted share in Q2 2023. We ended the Q1 of 2024 with $62,800,000 in cash and cash equivalents. In the Q2 of 2024, we had a strong quarter of cash generation of nearly $5,000,000 As of August 5, 2024, we have acquired 929 Bitcoins at an aggregate purchase price of $63,000,000 inclusive of fees and expenses. Speaker 400:11:31Cash, cash equivalents and restricted cash at June 30, 2024 was $7,500,000 Outside of working capital need, we intend to use our liquid assets, including operating cash generation to acquire more Bitcoin. In early June, we filed a shelf registration statement on Form S-three with amendments filed on July 11 July 31, 2024, under which we may, from time to time, offer, issue and sell debt securities, common stock and or warrants with a total value of up to $150,000,000 once the registration statement is declared effective by the SEC. At the same time, we filed a $50,000,000 at the market or ATM offering prospectus covering the offering, issuance and sale of common stock. The S3 is not yet effective. When effective, we intend to utilize the ATM when market conditions are favorable and we'll use the proceeds primarily for general corporate purposes, including the acquisition of Bitcoin. Speaker 400:12:44That concludes our prepared remarks. We'll now begin our Q and A. So we received a lot of great questions ahead of the release, and I will address a few of these that we did not address in the prepared remarks already. We do have the first question here. It's for Eric. Speaker 400:13:06How did you decide to embark on your Bitcoin strategy? And do you plan on purchasing cryptocurrency other than Bitcoin? Speaker 200:13:15Thanks, Renee. We've had a successful medical technology operating company with high cash generation and minimal capital needs. And along the way, we've accumulated a large cash balance of nearly $63,000,000 And as we have been looking for ways to deploy this cash to maximize shareholder value, our Board and our senior leadership decided that buying Bitcoin made sense as an investment. Our decision was influenced by MicroStrategy success and the increasing institutional ownership of Bitcoin as we've seen with the tens of 1,000,000,000 of dollars of inflows into the Bitcoin ETFs and investments in them by pension funds, endowments, banks, investment advisors. We believe that Bitcoin's unique attributes, including its ultimate finite supply, its discounted value versus gold, its decentralized structure and its growing global acceptance, differentiated from fiat money and also from other cryptocurrency assets. Speaker 200:14:24And we have no plans to purchase cryptocurrency assets other than Bitcoin. Speaker 400:14:32Thanks, Eric. I can take our next question. What's driving the underlying trends in the business? And what do you expect for the remainder of the year? So we are still experiencing demand for software licenses related to our QuantiBlade product. Speaker 400:14:49We're seeing continued testing and are obtaining new customers outside the managed care space, including at clinics and also at value based care providers, as the clinical value of testing really remains important. So our focus for the rest of the year will be to tightly control expenses and to maximize operating income. So outside of ensuring adequate working capital to run and grow our operating business, we do intend to deploy the remainder of our operating cash generation into additional Bitcoin purchases. So the next question here that we have is around our S3. So where are we in the S3 process and what capital instruments do you intend to use? Speaker 400:15:46We did initially file our stock registration on June 6 with the SEC. So once this becomes effective, it will allow us to issue up to 150,000,000 dollars in debt securities, common stock and or warrants. The SEC responded with questions primarily regarding our new Bitcoin strategy and disclosures around the same. We replied to their questions and comments and filed an amended S3 on July 11. And after reviewing, we're receiving further questions regarding our Bitcoin strategy, we did file another amended S-three on July 31. Speaker 400:16:29So we're waiting for the SEC to confirm that it has no further comments on the S3 and declare our S3 effective. So once effective, we do plan to tap our $50,000,000 ATM offering to issue equity, assuming, of course, that market conditions are favorable. We plan to use the ATM proceeds for general corporate purposes, including buying more Bitcoin. So given that we are an operating company and we do have solid cash generation and we're seeking to do additional financing, we do believe that we are in a strong position to build our Bitcoin arsenal over time. So it looks like we do have time for one more question. Speaker 400:17:18So Eric, this one is for you again. Can you talk about your long term strategy related to Bitcoin and initial reaction to your strategy? Speaker 200:17:31Sure. Great question. We're among a small number of public companies leading institutional Bitcoin adoption and the establishment of Bitcoin as a primary treasury reserve. And given our strong conviction in Bitcoin as a store of value and as a compelling investment, we intend to hold Bitcoin for the long term. We strongly believe that institutional adoption of Bitcoin will gain continued traction and drive overwhelming demand for it. Speaker 200:17:59I recently attended and spoke on a panel at Bitcoin 2024 in Nashville. There were 35,000 attendees at the conference, including 2 presidential candidates, several U. S. Senators and congressmen, and I was amazed by the outpouring and support that we received at the conference for our treasury reserve strategy. Semler Scientific has truly been embraced by the Bitcoin community, and we are thrilled. Speaker 400:18:30Thank you, Eric, and thank you, everyone, for your questions. As we wrap up this conference call, we wanted to emphasize our ongoing commitment for medical software licensing business and continued execution of our Bitcoin treasury strategy. We appreciate your participation in today's discussion, and thank you for your ongoing support. Operator? Operator00:18:53The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallSemler Scientific Q2 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Semler Scientific Earnings HeadlinesSemler Scientific, Inc. (NASDAQ:SMLR) Q1 2025 Earnings Call TranscriptMay 14 at 11:59 AM | msn.comSemler Scientific, Inc. (SMLR) Q1 2025 Earnings Call TranscriptMay 13 at 6:33 PM | seekingalpha.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 15, 2025 | Brownstone Research (Ad)Semler Scientific® Reports First Quarter 2025 Financial Results, BTC Yield of 22.2% YTD; Now holds 3,808 BTCMay 13 at 4:01 PM | prnewswire.comSemler Scientific Insider Ups Holding During YearMay 10, 2025 | finance.yahoo.comInsider Decision Unfolding At Semler Scientific: Douglas Murphy-Chutorian Exercises Options, Resulting In $0May 6, 2025 | benzinga.comSee More Semler Scientific Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Semler Scientific? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Semler Scientific and other key companies, straight to your email. Email Address About Semler ScientificSemler Scientific (NASDAQ:SMLR) provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.View Semler Scientific ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery? Upcoming Earnings NetEase (5/15/2025)Applied Materials (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Palo Alto Networks (5/19/2025)PDD (5/20/2025)Synopsys (5/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 5 speakers on the call. Operator00:00:01Good afternoon and welcome to the Semler Scientific 20 24 Second Quarter Financial Results Conference Call. Submitted prior to this call via e mail. Please note, this event is being recorded. Before we begin, Semler Scientific needs to remind you that certain comments made during this call may constitute forward looking statements and are made pursuant to and within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 as amended. These include statements regarding the expectations for expansion of the business and the development and the marketing of additional products, including receipt and timing of an additional 510 clearance for QuantaFlo and our recently adopted Bitcoin treasury strategy and plans to acquire additional Bitcoin. Operator00:01:10Such forward looking statements are subject to both known and unknown risks and uncertainties that could cause actual results to differ materially from such statements. Those risks and uncertainties are described in the press release and our SEC filings. The forward looking statements made today are as of the date of this call and the company does not undertake any obligation to update the forward looking statements. If you do not have a copy of today's release, you may obtain 1 by visiting the Investor Relations page of the website, semlarscientific.com. Now, I would like to introduce Doug Murphy Katorian, CEO of Semler Scientific. Operator00:01:51Please go ahead. Speaker 100:01:53Good afternoon, everybody. Thank you for joining our Q2 2024 results call. Once again, we achieved a strong interim from operations and used most of our cash and cash equivalents to purchase a bitcoin. We now hold a 929 bitcoins as of August 5, 2024. Now I'd like to hand the call over to Erik Semler, our Chairman, who will discuss our Bitcoin strategy in more detail. Speaker 200:02:34Eric? Thank you, Doug. It's great to be on the call today. In May, we announced that our Board of Directors adopted Bitcoin as our primary treasury reserve asset. We are very encouraged by the strong positive reaction to this announcement. Speaker 200:02:52We are in the fortunate position of being a company with a strong balance sheet, driven by a high margin business that has consistently generated cash. We are also fortunate that our Board members and executive officers collectively beneficially own approximately 30% of the company's outstanding shares and are intensely focused on maximizing shareholder value. Our Board and senior management have spent extensive time examining potential uses of cash, including acquisitions and stock repurchases. But after studying various alternatives, we decided that holding Bitcoin would be the best use of our cash. We view Bitcoin as a compelling investment. Speaker 200:03:39We are encouraged by the growing global acceptance and institutionalization of Bitcoin, which has been accelerated by the SEC's approval in January 2024 of 11 Bitcoin Spot ETFs. These ETFs have reported tens of 1,000,000,000 of dollars of net inflows with investments from a large number of institutions, including global banks, pensions, endowments and registered investment advisers. It is currently estimated that more than 10% of all bitcoins are now held by institutions. We believe Bitcoin has unique attributes as a scarce and finite asset that can serve as a reasonable inflation hedge and safe haven amid global instability. Bitcoin is often compared to gold, which has been viewed as a dependable store of value throughout history. Speaker 200:04:30Like gold, Bitcoin is viewed as a scarce asset. The ultimate supply of Bitcoin is limited to 21,000,000 coins and approximately 94% of its supply already exists. We believe that Bitcoin's finite, digital and decentralized nature, as well as its architectural resilience make it preferable to gold, which has a market capitalization more than 16 times higher than the market cap of Bitcoin. Given our view that Bitcoin is a comparable and possibly better store of value than gold, we believe that Bitcoin will approach or exceed the value of gold over time. In light of the substantial gap in value between gold and Bitcoin, we believe that Bitcoin has the potential to generate outsized returns as it gains increasing acceptance as digital gold. Speaker 200:05:26We are highly committed to our Bitcoin strategy. As an operating company, we intend to use our cash flow as well as proceeds from equity capital raises to accumulate Bitcoin. Now, I'm pleased to introduce our COO, Jennifer Oliva Harrington to provide an overview and update of our core medical products and services business. Jen? Speaker 300:05:49Thank you, Eric. Today, I will be presenting an overview of our market developments and opportunities. Renee Cormier, our CFO, will be providing information about Q2 2024 financial results. Semler is a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases. In conjunction with our Bitcoin treasury strategy, we will continue to focus on our core medical products and services business. Speaker 300:06:19We remain dedicated to our customers and our goal of operating a growing and profitable healthcare company. Our main product, QuantaFlo, is a medical device that is a non invasive point of care test that measures arterial blood flow in the extremities to aid clinicians in the early diagnosis of peripheral arterial disease or PAD. Our technology brings cardiovascular testing to the front lines of medicine. We have a high leverage distribution model as quantiflo was sold on a SaaS basis with a high recurring revenue stream from this subscription based licensing model that has a large and underpenetrated TAM. Sendler's operating focus remains supporting the identification of chronic diseases by our customers, which continues to burden our healthcare system. Speaker 300:07:10Cardiovascular disease ranks as a top concern in healthcare expenditures and global mortality, underscoring the imperative for early identification of cardiac existing products and data services to stay in the forefront of innovation and consistently deliver cutting edge solutions to our customers. Our long term vision includes extending our reach to encompass additional cardiovascular applications, reflecting dedication to continuous expansion. In the interim, we continue the promotion and selling of QuantaFlo as a valuable aid in the diagnosis of PAD. We continue seeking to further establish QuantaFlo as standard of care for our PAD diagnosis, leveraging the demonstrated clinical benefit of early detection and preventative care. We believe this approach holds the potential to not only save lives, but also to lower healthcare expenditures. Speaker 300:08:13We will continue diversifying our customer base by adding new medical centers, expanding our reach within value based care providers and growing opportunities within additional markets that will benefit from PAD testing. I will now turn the call over to Renee to discuss our financial highlights. Speaker 400:08:32Thank you, Jen. I'll cover our Q2 financial results and then speak more about our Bitcoin holdings and recently filed S 3. Following our remarks and as time permits, we will answer questions that have been submitted via email. Total revenues in Q2 2024 were $14,500,000 which was down about 22% compared to the Q2 of 2023. For the remainder of 2024, we anticipate our revenues could follow a similar cadence that we saw in 2023, with H1 more heavily weighted versus H2. Speaker 400:09:11In the Q2 of 2024, our 3 largest customers, including their related affiliates, comprised 44%, 27% and 11% of quarterly revenues, respectively. Operating expenses in Q2 2024, which includes cost of revenues, were $9,100,000 a decrease of 20% year over year. Income from operations was $5,400,000 compared to $7,200,000 in the prior year. For the remainder of the year, we are focused on tight expense control as we continue to implement our Bitcoin treasury strategy. Other expenses net was $4,200,000 and included the change in fair value of our Bitcoin holdings of negative $5,100,000 We have elected to early adopt ASU 20,203, which is the new standard issued by the FASB for accounting for and disclosure of crypto assets. Speaker 400:10:20ASU 20,203,008 requires Bitcoin assets to be measured at fair value with gains and losses from changes in the fair value to be recognized in net income for each reporting period. While this may introduce volatility into our reported net income, it will not impact our cash flow from operations, which we intend to invest in additional Bitcoin purchases. Net income was nil or $0 per basic share and $0 per fully diluted share compared to net income of $5,900,000 or $0.88 per basic share and $0.75 per fully diluted share in Q2 2023. We ended the Q1 of 2024 with $62,800,000 in cash and cash equivalents. In the Q2 of 2024, we had a strong quarter of cash generation of nearly $5,000,000 As of August 5, 2024, we have acquired 929 Bitcoins at an aggregate purchase price of $63,000,000 inclusive of fees and expenses. Speaker 400:11:31Cash, cash equivalents and restricted cash at June 30, 2024 was $7,500,000 Outside of working capital need, we intend to use our liquid assets, including operating cash generation to acquire more Bitcoin. In early June, we filed a shelf registration statement on Form S-three with amendments filed on July 11 July 31, 2024, under which we may, from time to time, offer, issue and sell debt securities, common stock and or warrants with a total value of up to $150,000,000 once the registration statement is declared effective by the SEC. At the same time, we filed a $50,000,000 at the market or ATM offering prospectus covering the offering, issuance and sale of common stock. The S3 is not yet effective. When effective, we intend to utilize the ATM when market conditions are favorable and we'll use the proceeds primarily for general corporate purposes, including the acquisition of Bitcoin. Speaker 400:12:44That concludes our prepared remarks. We'll now begin our Q and A. So we received a lot of great questions ahead of the release, and I will address a few of these that we did not address in the prepared remarks already. We do have the first question here. It's for Eric. Speaker 400:13:06How did you decide to embark on your Bitcoin strategy? And do you plan on purchasing cryptocurrency other than Bitcoin? Speaker 200:13:15Thanks, Renee. We've had a successful medical technology operating company with high cash generation and minimal capital needs. And along the way, we've accumulated a large cash balance of nearly $63,000,000 And as we have been looking for ways to deploy this cash to maximize shareholder value, our Board and our senior leadership decided that buying Bitcoin made sense as an investment. Our decision was influenced by MicroStrategy success and the increasing institutional ownership of Bitcoin as we've seen with the tens of 1,000,000,000 of dollars of inflows into the Bitcoin ETFs and investments in them by pension funds, endowments, banks, investment advisors. We believe that Bitcoin's unique attributes, including its ultimate finite supply, its discounted value versus gold, its decentralized structure and its growing global acceptance, differentiated from fiat money and also from other cryptocurrency assets. Speaker 200:14:24And we have no plans to purchase cryptocurrency assets other than Bitcoin. Speaker 400:14:32Thanks, Eric. I can take our next question. What's driving the underlying trends in the business? And what do you expect for the remainder of the year? So we are still experiencing demand for software licenses related to our QuantiBlade product. Speaker 400:14:49We're seeing continued testing and are obtaining new customers outside the managed care space, including at clinics and also at value based care providers, as the clinical value of testing really remains important. So our focus for the rest of the year will be to tightly control expenses and to maximize operating income. So outside of ensuring adequate working capital to run and grow our operating business, we do intend to deploy the remainder of our operating cash generation into additional Bitcoin purchases. So the next question here that we have is around our S3. So where are we in the S3 process and what capital instruments do you intend to use? Speaker 400:15:46We did initially file our stock registration on June 6 with the SEC. So once this becomes effective, it will allow us to issue up to 150,000,000 dollars in debt securities, common stock and or warrants. The SEC responded with questions primarily regarding our new Bitcoin strategy and disclosures around the same. We replied to their questions and comments and filed an amended S3 on July 11. And after reviewing, we're receiving further questions regarding our Bitcoin strategy, we did file another amended S-three on July 31. Speaker 400:16:29So we're waiting for the SEC to confirm that it has no further comments on the S3 and declare our S3 effective. So once effective, we do plan to tap our $50,000,000 ATM offering to issue equity, assuming, of course, that market conditions are favorable. We plan to use the ATM proceeds for general corporate purposes, including buying more Bitcoin. So given that we are an operating company and we do have solid cash generation and we're seeking to do additional financing, we do believe that we are in a strong position to build our Bitcoin arsenal over time. So it looks like we do have time for one more question. Speaker 400:17:18So Eric, this one is for you again. Can you talk about your long term strategy related to Bitcoin and initial reaction to your strategy? Speaker 200:17:31Sure. Great question. We're among a small number of public companies leading institutional Bitcoin adoption and the establishment of Bitcoin as a primary treasury reserve. And given our strong conviction in Bitcoin as a store of value and as a compelling investment, we intend to hold Bitcoin for the long term. We strongly believe that institutional adoption of Bitcoin will gain continued traction and drive overwhelming demand for it. Speaker 200:17:59I recently attended and spoke on a panel at Bitcoin 2024 in Nashville. There were 35,000 attendees at the conference, including 2 presidential candidates, several U. S. Senators and congressmen, and I was amazed by the outpouring and support that we received at the conference for our treasury reserve strategy. Semler Scientific has truly been embraced by the Bitcoin community, and we are thrilled. Speaker 400:18:30Thank you, Eric, and thank you, everyone, for your questions. As we wrap up this conference call, we wanted to emphasize our ongoing commitment for medical software licensing business and continued execution of our Bitcoin treasury strategy. We appreciate your participation in today's discussion, and thank you for your ongoing support. Operator? Operator00:18:53The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.Read morePowered by